Option Chain

Biomarin Pharmaceutical Inc

BMRNNASDAQ · USD

56.03USD-0.09 (-0.16%)

477

Biomarin Pharmaceutical Inc (BMRN) Option Chain

Biomarin Pharmaceutical Inc trades at $56.03, down 0.16%, with an IV Rank of 31.35%. This is average versus the past year, and the company carries a market cap of $10,870M in the Biotechnology industry. On the Nov 20, 2026 chain, the at the money $55.00 strike shows calls at $2.05 / $3.10 and puts at $0.75 / $1.50, both carrying about $1.33 of extrinsic value and a roughly 50% probability of expiring out of the money. Volume is heaviest on the $60.00 calls, at 467 contracts, and the $55.00 puts, at 2, as of Nov 5, 2026.

Tracking the BMRN option chain helps you see every strike and expiry on Biomarin Pharmaceutical Inc in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of BMRN options activity at a glance. Use our scanner to monitor the BMRN option chain in real time and filter for the trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For BMRN stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where BMRN options are being actively traded, and where they are not.

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase.

CALLs									PUTs
Prob. OTM %	Open Interest	Volume	Extrinsic Value	Intrinsic Value	Bid	Ask	Strike	Moneyness %	Bid	Ask	Intrinsic Value	Extrinsic Value	Volume	Open Interest	Prob. OTM %
7.02	1	0	0.52	6.03	4.50	8.60	50.00	-10.91	0.05	1.50	0.00	0.78	0	105	92.98
19.93	0	0	1.42	3.53	3.60	6.30	52.50	-6.45	0.15	1.15	0.00	0.65	0	51	80.07
40.41	1,302	0	1.54	1.03	2.05	3.10	55.00	-2.00	0.75	1.50	0.00	1.13	2	234	59.59
62.99	496	137	1.58	0.00	0.90	2.25	57.50	+2.46	1.70	2.75	1.47	0.76	0	232	37.01
81.10	2,001	467	0.50	0.00	0.25	0.75	60.00	+6.91	3.70	5.00	3.97	0.38	0	584	18.90

As of Nov 5, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →

Stock Statistics

IndustryBiotechnology
SectorHealthcare
IV Rank31.35% Moderate
Market cap (M$)10,870
52 weeks high-20.94%
52 weeks low13.93%
Analyst recommendationBuy
1.55
Target price$90.81
63.52% above the current stock price
Dividend—
Payout ratio0.00%
Earnings date2026-11-02
P/E—
Future P/E8.83
EPS (ttm)-0.10
EPS growth next 5 years62.21%

As of Nov 5, 2026

Browse all Option Chain tickers